Linezolid and atorvastatin impact on pneumonia caused by *Staphylococcus aureus* in rabbits with or without mechanical ventilation

Laure-Anne Pauchard¹, Mathieu Blot¹,², Rémi Bruyere¹, Saber-Davide Barbar¹, Delphine Croisier³, Lionel Piroth², Pierre-Emmanuel Charles¹,⁴*

¹ Laboratoire “Lipides Nutrition Cancer”, U.M.R. 1231, I.N.S.E.R.M., U.F.R. Sciences de Santé, Université de Bourgogne, Dijon, France, ² Service des Maladies Infectieuses et Tropical es, Hôpital F. Mitterrand, Dijon, France, ³ Vivexia S.A.R.L., Gémeaux, France, ⁴ Service de Réanimation Médicale, Hôpital F. Mitterrand, Dijon, France

* pierre-emmanuel.charles@chu-dijon.fr

Abstract

Pneumonia may involve methicillin-resistant *Staphylococcus aureus* (MRSA), with elevated rates of antibiotics failure. The present study aimed to assess the effect of statins given prior to pneumonia development. Spontaneously breathing (SB) or mechanically ventilated (MV) rabbits with pneumonia received atorvastatin alone, linezolid (LNZ) alone, or a combination of both (n = 5 in each group). Spontaneously breathing and MV untreated infected animals (n = 11 in each group), as well as uninfected animals (n = 5 in each group) were used as controls. Microbiological features and inflammation were evaluated. Data are presented as medians (interquartile range). Linezolid alone tended to reduce pulmonary MRSA load in both SB and MV rabbits, but failed to prevent bacteremia (59%) in the latter. Linezolid alone dampened TNF-α lung production in both SB and MV rabbits (e.g., 2226 [789] vs. 11478 [10251] pg/g; p = 0.022). Statins alone did the same in both SB and MV animals (e.g., 2040 [133]; p = 0.016), and dampened systemic inflammation in the latter, possibly through TLR2 down-regulation within the lung. However, the combination of LNZ and statin led to an increased rate of bacteremia in MV animals up to 75%. Statins provide an anti-inflammatory effect in rabbits with MRSA pneumonia, especially in MV ones. However, dampening the systemic inflammatory response with statins could impede blood defenses against MRSA.

Introduction

Methicillin-resistant *Staphylococcus aureus* (MRSA) in both community and ventilator-associated pneumonia (VAP) is frequent in some countries. The highest clinical success rates did not exceed 57% despite appropriate antibiotics [1].

Experimental evidence suggests that mechanical ventilation (MV) could cause specific lung damage (i.e., ventilator-induced lung injury [VILI]) [2]. Moreover, MV could *per se* modify...
the efficacy of lung immunity and promote an overwhelming inflammatory state if pneumonia develops [3–6]. Actually, a link has been shown between the magnitude of pulmonary and systemic inflammatory responses and outcomes in VAP patients [7].

Statins are lipid-lowering agents that possess immunomodulatory properties that could be in part mediated by the down-regulation of the toll-like receptors (TLRs), involved in pathogens recognition by immune cells [8, 9]. Among TLRs, TLR-2 is likely to sense the immune response to *S. aureus* [10]. Statins could be protective in pneumonia according to some concordant clinical data [11, 12]. In addition, experimental studies have demonstrated a lung-protective effect through VILI attenuation [13, 14]. Outcomes in VAP patients were improved by prior treatment with statins [15]. This remains however a controversial issue [16].

We hypothesized that statins could influence the course of MRSA pneumonia in a rabbit model [17]. We used spontaneously breathing (SB) and ventilated animals treated with linezolid (LNZ), atorvastatin or the combination of both, to assess the effect of statins in both settings (i.e. MRSA pneumonia with or without MV).

### Materials and methods

#### Animal and study design

Male New Zealand White rabbits (3.0 [0.2] Kg) were bred in the University of Burgundy animal facility (Dijon, France). Animal use and handling were approved by the local veterinary committee (i.e., Comité d’Ethique de l’Expérimentation Animale Grand Campus Dijon [C2EA-105]), and were performed according to the European laws for animal experimentation in accordance with current recommendations mentioned in the *Guide for the Care and Use of Laboratory Animals*, National Institutes of Health No. 92–23, revised 1985. Animals were randomized into the SB or MV group within each experiment as follows: control uninfected (SB or MV, n = 5 in each), infected (SB+MRSA [n = 11] or MV+MRSA [n = 11]), statin pretreatment infected (SB+MRSA+Statin or MV+MRSA+Statin, n = 5 in each), LNZ-treated infected group (SB+MRSA+LNZ or MV+MRSA+LNZ, n = 5 in each) and the statin pretreatment LNZ-treated infected group (SB+MRSA+Statin+LNZ or MV+MRSA+Statin+LNZ, n = 5 in each).

#### Mechanical ventilation

Under general anesthesia provided by ketamine 3.3 mg/Kg (Panpharma, France) and xylazine 1 mg/Kg (Rompun®, Bayer, Germany), a cuff tube of 2.5 mm (Mallinckrodt™, Covidien®, U.S.A.) was inserted through the mouth into the trachea under view control. The animal was connected to a volume-controlled respirator (Servo ventilator 900C, Siemens®, Germany) (tidal volume of 12 mL/Kg with zero end-expiratory pressure [ZEEP], a respiratory rate of 25 bpm and an 0.5 inspired fraction of O₂). Rabbits were kept anesthetized and paralyzed throughout the experiment with midazolam (0.06 mg/Kg/h) (Hypnovel®, Roche, Switzerland) and cisatracurium besilate (0.3 mg/Kg/h) (Nimbex®, GlaxoSmithKline, U.K). Isotonic serum was infused.

#### Methicillin-resistant *Staphylococcus aureus* pneumonia induction

The USA300 PVL- strain of *S. aureus* was used. At 48 hours before experimentation began, several colonies were harvested, cultured on MRSA2 agar plates (Biomérieux) and then incubated for 24 hours at 37°C. One colony was inoculated into 10 mL of BHI and was incubated for 6 hours before being cultured for 18 hours. A mean titer 9.5 Log₁₀ colony-forming units per milliliter (CFU/mL) was used [17]. In the SB groups, inoculum (0.5 mL) was gently flushed...
through a catheter briefly introduced into the trachea. The animals were then placed upright for 15s and allowed to go back to their cage before being sacrificed 24 hours later. In the MV groups, animals were subjected to MV for 24 hours before being instilled intrabronchially with MRSA. The animals were then kept under MV for 24 hours before sacrifice. Controls received 0.5 mL of saline.

**Statin pre-treatment**

Rabbits were pre-treated with statin (20 mg/Kg, as previously described) (Atorvastatin, Pfizer AG, Zürich) by intra-gastric administration, 72, 48 and 24 hours before infection with MRSA [13, 14].

**Linezolid treatment and concentrations**

Linezolid (Zyvoxid®, Pfizer, United States) was delivered (125 mg of LNZ in 10 mL of 5% α-cyclodextrin solution) over 1 day through two subcutaneous injections (50 mg/kg), 4 and 16 hours after bacterial challenge, as previously described [18]. Blood samples were obtained 1, 2, 4, 6 and 12 hours after the first drug injection and stored at -80˚C. Linezolid concentrations were then determined by high-performance liquid chromatography (limit of detection = 0.03 mg/L).

**Material harvesting**

Blood samples were collected (24 hours before bacterial challenge, and then 0, 12 and 24 hours after) and centrifuged at 1,000 g for 15 minutes at 4˚C; the supernatant was divided into aliquots and stored at -80˚C for cytokine concentration measurements.

All the animals were sacrificed by an intravenous overdose of thiopental (100 mg/kg) and then exsanguinated. Autopsies were carried out so that the lungs and spleen were aseptically taken. They were harvested for ribonucleic acid (RNA) extraction and microscopic examination. The remaining tissue was homogenized to determine cytokine concentrations and for bacterial culture.

**Histological analysis**

A tissue sample of 1 cm³ that focused on a macroscopic lesion was fixed in formalin and embedded in paraffin. Five-micrometer sections were obtained and colored with hematoxylin and eosin. After viewing five fields per sector in a blinded manner, each section was assigned a numerical histologic score ranging from 0 to 3 according to the degree of PMN infiltration, hemorrhage, and edema in the interstitial and alveolar spaces [19].

**Microbiological evaluation of pneumonia**

Each pulmonary lobe was isolated from the whole lung, homogenized and used for serial tenfold dilution cultures. The mean pulmonary bacterial concentration was calculated (i.e. mean concentration = Σ [lobar concentration x lobar weight]/ lobar weights). Spleens were processed similarly. An *S. aureus*-positive spleen culture was considered a marker of bacteremia.

**Whole blood assay**

Fresh heparinized blood from spontaneously breathing (SB) untreated rabbits (n = 10), rabbits subjected to 24-hour MV as described above (n = 5), or either SB or MV rabbits given atorvastatin (20 mg/kg once a day) 72 hours prior to venipuncture was obtained and diluted 1:2 with RPMI 1640 medium (Gibco™ Life Technologies, Saint Aubin, France). Blood was plated at
120 μL/well in a 96-well plate and incubated for 15 minutes at 37°C. Atorvastatin pills were dissolved in RPMI 1640 medium (10 nmol/mL in final volume), added to whole blood (60 μL/well) and incubated for 24 hours at 37°C. Then, heat-killed S. aureus (HKSA) were added and the blood was incubated for 24 hours at 37°C [17]. Cell viability was checked (propidium iodide dying assay) and culture supernatants were finally removed and kept frozen at -80°C until cytokine concentrations were determined.

Cytokine measurements

TNF-α and IL-8 concentrations were measured using rabbit specific enzyme-linked immunosorbent assay (ELISA) kits (Uscn Life Science Inc., Wuhan, China). The lower limit was 15.6 picograms/mL for both TNF-α and IL-8.

Quantitative Real Time (RT)-Polymerase Chain Reaction (PCR)

RNA was extracted from lung samples using the RNA GenElute kit (Sigma-Aldrich, St Louis, MO, USA). Quantitative PCR was performed using IQ Sybergreen Supermix (Bio-Rad, Hercules, CA, USA). Melting curves were performed to ensure the presence of a single amplicon. The following primers were used: rTlr2, forward 5’-TGT CTG TCA CCG AAC CGA ATC CAC-3’ and reverse 5’-TCA GGT TTT TCA GCG TCA GCA GGG-3’ [20]; and rGapdh, forward 5’-ATG TTT GTG ATG GGC GTG AAC C-3’ and reverse 5’-CCC AGC ATC GAA GGT AGA GGA-3’.

The results are expressed as the fold induction using the ΔCt method since the SB animals were considered as the baseline condition.

Statistical analysis

Data were expressed as means (standard deviations) or medians (interquartile ranges) if not normally distributed. Group sizes were determined pragmatically according to previous experiments [6]. Continuous variables between the different treatment arms (i.e., atorvastatin alone, LNZ alone or the combination of both, in either SB or MV animals) were compared using 2-way ANOVA, the non-parametric Mann-Whitney U test or the Kruskall-Wallis test, as appropriate, and post hoc corrections for multiple comparisons were applied. The Fisher exact test was used for the comparison of categorical variables. All tests were two-tailed. A p value lower than 0.05 was considered significant.

Prism software was used (GraphPad, San Diego California, USA).

Results

Statin treatment prior to pneumonia did not improve linezolid efficacy

There was a trend toward a reduction of the pulmonary bacterial load in SB and in MV rabbits treated with LNZ, without any improvement in tissue damage (Figs 1 and 2). However, whereas no bacteremia was detected in the SB treated rabbits, LNZ failed apparently to prevent MRSA systemic spillover in MV animals since 59% of them had positive spleen cultures (Fig 1).

Statin therapy alone was associated with a trend towards a greater bacterial burden within the lung, especially in the MV rabbits (183% vs. 26% of the inoculum; p = 0.051), and aggravated lung injury in these animals (Figs 1 and 2).
Statin treatment prior to pneumonia modified the pulmonary host response

Pneumonia development was associated with the release of large amounts of IL-8 and TNF-α within the lung, whether rabbits underwent MV or not (Fig 3).

Linezolid treatment significantly reduced lung inflammation in both the SB and MV groups in terms of TNF-α concentrations (e.g., 2226 [789] vs. 11478 [10251] pg/g in the MV animals; p = 0.022), but not IL-8’s.

Statin treatment alone decreased the release of TNF-α, but not IL-8, in both SB and MV rabbits (e.g., 2040 [133] vs. 11478 [10251] pg/g in the MV animals; p = 0.016).

In animals treated with LNZ, previous statin therapy did not provide an additional anti-inflammatory effect.

Statin treatment prior to pneumonia modified the systemic inflammatory response

Statin alone reduced IL-8 blood concentrations in MV infected animals (155% [55] vs. 309% [128] of the baseline value in the MV animals; p = 0.032) (Fig 4).

Significantly lower blood levels of IL-8 were achieved in SB rabbits treated with atorvastatin prior to pneumonia and then treated with LNZ 24 hours following the bacterial challenge than in rabbits treated with LNZ alone. The same additive anti-inflammatory effect of statin was observed in MV rabbits according to TNF-α blood levels as early as the 8th hour following the onset of infection (75% [22] vs. 169% [56] of the baseline value; p < 0.001).

According to spleen levels of inflammatory cytokines, prior statin treatment alone and the combination of statin and LNZ significantly dampened IL-8 systemic release in MV animals at least, whereas LNZ alone did not (Fig 3).
Antibiotics and statins in experimental pneumonia

(A)

(B)
Of note, MV alone did not influence significantly both IL-8 and TNF-α blood as well as spleen concentrations (Figs 3 and 4). After HKSA ex vivo stimulation, levels of both IL-8 and TNF-α were higher in the blood taken from MV rabbits (Fig 5). If MV rabbits were given statin prior to MV, or if the drug was added to the medium prior to ex vivo stimulation, TNF-α levels were significantly decreased as low as baseline values.

Atorvastatin treatment decreased pulmonary and systemic expression of TLR2

Statin treatment decreased tlr2 expression within the lung of only SB animals (Fig 6), and significantly dampened tlr2 expression in the spleen of both groups.

Discussion

We showed herein in a rabbit model of MRSA pneumonia that, although LNZ was efficient in keeping in check bacterial growth within the lung of both SB and MV animals, infection could be considered as more severe in the latter, since pulmonary-to-systemic translocation of S. aureus was apparently not prevented by LNZ in the ventilated animals. The lung inflammatory response was in part dampened by LNZ in both SB and MV rabbits, but interestingly, an additive effect was achieved by pre-treatment with atorvastatin. Similarly, we showed that LNZ alone failed to completely abrogate the systemic release of inflammatory mediators subsequent to pneumonia, whereas its combination with atorvastatin succeeded in doing so. This anti-inflammatory effect, however, could have hampered the host’s ability to control systemic diffusion of S. aureus, thereby promoting bacterial spillover into the bloodstream in MV animals.

Cumulative experimental evidence supports the notion that MV itself, especially if adverse settings including large V_T are applied, could be harmful in the context of bacterial pneumonia by promoting pulmonary and systemic inflammation [17, 21, 22]. In the present study, we showed that although LNZ therapy was successful in SB rabbits, its efficacy was limited to the lung compartment in MV rabbits. Interestingly, our findings in our model of pneumococci pneumonia treated with moxifloxacin were similar [23]. No significant histological findings were likely to account for such a difference in extra-pulmonary bacterial diffusion, but unseen lung damage is not excluded.

The pulmonary release of TNF-α was reduced by LNZ in both SB and MV rabbits, as was the bacterial burden. It remains unclear as to what extent the anti-inflammatory properties of LNZ per se contributed to such a decrease in this key mediator. Actually, experimental studies have shown that LNZ was able to reduce pulmonary inflammation in mice with MRSA pneumonia, in terms of MIP-2 concentrations, thus limiting in turn PMN recruitment and lung injury [24]. In addition, since high levels of IL-8 were still reached despite LNZ therapy, the net effect on lung inflammation is uncertain. Thus, no positive beneficial effect on tissue injury was found.
Treatment with atorvastatin prior to the bacterial infection had anti-inflammatory effects per se in the infected lung of both SB and MV animals according to TNF-α concentrations, as reported in vitro [9, 25]. It has been shown that human alveolar macrophages incubated with simvastatin released lower amounts of inflammatory mediators in response to a TLR2 agonist, and statin pretreatment decreased lung inflammation following lipopolysaccharide inhalation in volunteers [9, 26].
Fig 4. Time course of serum inflammatory cytokine concentrations during experiment. Serum concentrations of interleukin (IL)-8 and tumor necrosis factor (TNF)-α expressed as % of the mean baseline value measured by enzyme-linked immune-sorbent assay at baseline (100%; 24 hours before bacterial airway challenge), just before intra-tracheal instillation of 10⁹ CFU of S. aureus (H0), and then 8 (H8) and 24
However, statin therapy alone tended to decrease pulmonary bacterial clearance in MV animals, leading in turn to worse lung injury, thus underlining the need for efficient antimicrobial therapy in combination with the drug. These findings emphasize also the fact that the beneficial effect of statins on VILI is uncertain and should be balanced with their deleterious impact on bacterial clearance [13]. Moreover, the enhanced bactericidal activity of PMNs reported in mice with *S. aureus* pneumonia treated with simvastatin is unlikely in our model [27]. Appropriate antibiotics could thus be the prerequisite for any beneficial adjunctive effect of statin therapy in patients with VAP.

The magnitude and persistence of the systemic inflammation are considered key determinants of outcomes in the setting of VAP [7]. Atorvastatin pretreatment could blunt the host inflammatory response within the blood compartment as reported in animal models of sepsis [28]. However, it may be deleterious in our model since bacteremia is an independent predictor of death in MRSA VAP patients [29]. Linezolid might have immuno-modulatory properties likely to dampen MRSA virulence factors, including the expression of pro-inflammatory cytokines.

**Fig 5. Inflammatory cytokines in whole blood stimulated *ex vivo* by *S. aureus* in various conditions.** Interleukin (IL)-8 and tumor necrosis factor (TNF)-α mean levels (SD) in the supernatant of whole blood from either spontaneously breathing rabbits or animals subjected to mechanical ventilation. Atorvastatin was added to the medium (“statin”) or given to the rabbit prior to blood sampling (“Premed”). Values are presented as means (SD). 2-way ANOVA test was used for all intergroup comparisons with Tukey’s adjustment for multiple comparisons. One missing [IL-8] and one missing [TNF-α] value in the Whole blood+MRSA and in the Whole blood+MRSA+statin groups. MRSA: methicillin-resistant *S. aureus*; SB: spontaneously breathing; MV: mechanical ventilation; SD: standard deviation.
signals and could thus be beneficial in a mouse model of pneumonia despite persisting bacteremia [30]. Accordingly, the overall effect of the combination of atorvastatin and LNZ could protect the host against a protracted systemic inflammatory response, although delaying *S. aureus* clearance from the blood compartment. However, further experimental studies are necessary before any definitive conclusions can be drawn.

Statins exert various immunomodulatory effects but the underlying mechanisms remain unclear [8]. Data from *in vitro* studies suggest that statins could interfere with the TLR pathway, thereby modulating the response to microbial products. However, depending on the experimental model, the net effect of statin treatment could be pro- or anti-inflammatory [25, 31]. For instance, statins could have anti-inflammatory effects through TLR down-regulation [31]. Accordingly, we found that TLR2 gene expression down-regulation by statin within the lung could account for its anti-inflammatory effect. Interestingly, this is in line with previous findings from our group and others showing that *tlr2* up-regulation within the lung of animals subjected to MV probably accounted for overreaction to its agonist including *S. aureus* cell wall compounds [6, 32]. In contrast, other mechanisms are probably involved within the blood, suggesting that the spleen was a surrogate for peripheral blood mononuclear cells [33]. Moreover, the effects of statin probably depend on the molecule tested, the cell type and its environment, as well as both dose and duration of treatment prior to stimulation. Herein, we showed that despite one negative effect of atorvastatin treatment prior to pneumonia, namely the systemic release of IL-8 in MV rabbits, *ex vivo* experiments showed that whole blood taken from pretreated MV rabbits overreacted to HKSA stimulation in terms of IL-8 production. These findings, as well as *in vitro* studies, illustrate to what extent impact of statin on the inflammatory response is equivocal.

Although experimental findings support the protective impact of statins in the setting of VAP, strong clinical evidence is still lacking. Actually, the only large multicenter RCT published so far showed that atorvastatin had no effect on the outcome of patients with suspected VAP [34]. However, we have shown that statin treatment prior to VAP was an independent predictor of ICU survival [15]. Similarly, it has been shown by one RCT that overall mortality
was reduced in patients with the most severe VAP who received statin prior to infection, as already demonstrated previously in another trial, which included patients with sepsis from various origins [35, 36]. Thus, one cannot exclude the possibility that statins could be beneficial to the host only if given prior to the infection, as was the case in our model. Several explanations could be proposed: (i) more than one administration of the drug is required before critical concentrations in the blood and lung are reached; (ii) the clinical suspicion of VAP is probably later than the actual onset of pneumonia (i.e., airway challenge with bacteria triggering the immune response); (iii) immunomodulation has to occur very early during sepsis in order to prevent any overwhelming pro-inflammatory response.

Several limitations of our study should be mentioned. First, the MV with “high” $V_T$ and without PEEP we used could be considered not clinically relevant. However, it has recently been reported that such settings were still used, especially in the operating room [37]. In addition, it is known that lung injury is heterogeneous in ARDS patients. As a result, poorly aerated areas of the lung usually coexist with overstretched ones, even if “low-$V_T$” is applied, as shown in human studies [38]. It is therefore quite possible that such parts of the lung may react as described in the present study if bacterial challenge occurred in patients subjected to “protective” MV. Third, TLR2 assessment was limited to gene expression, and the corresponding protein was not measured. Fourth, our study may be underpowered given the small size of the experimental groups. In addition, we should acknowledge that the LNZ concentrations achieved in the treated animals did not reach the usually reported values in humans, thereby undermining the clinical relevance of our findings (Fig 7). However, we used a MRSA strain, for which the MIC for LNZ was low (i.e., 1 mg/L). In addition, it has recently been shown that the LNZ concentration actually obtained in critically ill patients, especially those with lung injury, were probably not as high as those in healthy volunteers [39]. Finally, our model does not exactly mimic the pathophysiology of VAP since a large number of bacteria were directly inoculated into the airways rather than repeatedly inhaled in small numbers. In addition, there was no mortality attributable to pneumonia in our model, at least over the 48-hour observation period. As a result it remains difficult to evaluate the clinical relevance of our findings.
Conclusions
Atorvastatin treatment prior to pneumonia provides an anti-inflammatory effect within the lung and the systemic compartment of rabbits with MRSA pneumonia treated by LNZ. This effect may be mediated at least in part by TLR2 down-regulation. Whether such an impact is beneficial for the host remains unclear.

Supporting information
S1 File. Main raw data and statistical analysis reports.
(ZIP)

Acknowledgments
We are indebted to G. Lina (Lyon, France) who kindly provided the *Staphylococcus aureus* strain used in this study, P. Guerard who performed linezolid measurements and P. Bastable for editing assistance.

Author Contributions
Conceptualization: Pierre-Emmanuel Charles.
Data curation: Pierre-Emmanuel Charles.
Formal analysis: Laure-Anne Pauchard, Mathieu Blot, Pierre-Emmanuel Charles.
Funding acquisition: Pierre-Emmanuel Charles.
Investigation: Laure-Anne Pauchard, Mathieu Blot, Rémi Bruyere, Pierre-Emmanuel Charles.
Methodology: Laure-Anne Pauchard, Pierre-Emmanuel Charles.
Project administration: Laure-Anne Pauchard, Pierre-Emmanuel Charles.
Resources: Delphine Croisier.
Supervision: Lionel Piroth, Pierre-Emmanuel Charles.
Validation: Saber-Davide Barbar.
Visualization: Laure-Anne Pauchard, Mathieu Blot, Pierre-Emmanuel Charles.
Writing – original draft: Laure-Anne Pauchard, Pierre-Emmanuel Charles.
Writing – review & editing: Saber-Davide Barbar, Lionel Piroth.

References
1. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, et al. Linezolid in meticillin-resistant *Staphylococcus aureus* nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012; 54(5):621–9. https://doi.org/10.1093/cid/cir895 PMID: 22247123
2. Dreyfuss D, Saumon G. Ventilator-induced lung injury: lessons from experimental studies. Am J Respir Crit Care Med. 1998; 157(1):294–323. https://doi.org/10.1164/ajrccm.157.1.9604014 PMID: 9445314
3. Charles PE, Piroth L, Desbiolles N, Lequeu C, Martin L, Portier H, et al. New model of ventilator-associated pneumonia in immunocompetent rabbits. Critical care medicine. 2002; 30(10):2278–83. https://doi.org/10.1097/01.CCM.0000025914.47112.77 PMID: 12394956
4. Charles PE, Martin L, Etienne M, Croisier D, Piroth L, Lequeu C, et al. Influence of positive end-expiratory pressure (PEEP) on histopathological and bacteriological aspects of pneumonia during low tidal volume mechanical ventilation. Intensive care medicine. 2004; 30(12):2263–70. https://doi.org/10.1007/s00134-004-2442-7 PMID: 15536527
5. Moriyama K, Ishizaka A, Nakamura M, Kubo H, Kotani T, Yamamoto S, et al. Enhancement of the endotoxin recognition pathway by ventilation with a large tidal volume in rabbits. Am J Physiol Lung Cell Mol Physiol. 2004; 286(6):L1114–21. https://doi.org/10.1152/ajplung.00296.2003 PMID: 14633514

6. Charles PE, Tissieres P, Barbar SD, Croisier D, Dufour J, Dunn-Siegrist I, et al. Mild-stretch mechanical ventilation up-regulates toll-like receptor 2 and sensitizes the lung to bacterial lipopeptide. Critical care. 2011; 15(4):R181. https://doi.org/10.1186/cc10330 PMID: 21794115

7. van der Poll T, Opal SM. Host-pathogen interactions in sepsis. Lancet Infect Dis. 2008; 8(1):32–43. https://doi.org/10.1016/S1473-3099(07)70265-7 PMID: 18063412

8. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins and sepsis: multiple modifications at multiple levels. The Lancet Infectious Diseases. 2007; 7(5):358–68. https://doi.org/10.1016/S1473-3099(07)70111-1 PMID: 17448939

9. Wu BQ, Luo JM, Wang YH, Shi YF, Liu H, Ba JH, et al. Inhibitory effects of simvastatin on staphylococcus aureus lipoteichoic acid-induced inflammation in human alveolar macrophages. Clin Exp Med. 2014; 14(2):151–60. https://doi.org/10.1007/s10238-013-0231-z PMID: 23456570

10. Oliveira-Nascimento L, Massari P, Wetzler LM. The Role of TLR2 in Infection and Immunity. Front Immunol. 2012; 3:79. https://doi.org/10.3389/fimmu.2012.00079 PMID: 22566960

11. Leung S, Pokharel R, Gong MN. Statins and outcomes in patients with bloodstream infection: a propensity-matched analysis. Critical care medicine. 2012; 40(4):1064–71. https://doi.org/10.1097/CCM.0b013e31823bc9e7 PMID: 22202711

12. Chalmers JD, Singanagam A, Murray MP, Hill AT. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med. 2008; 121(11):1002–7 e1. https://doi.org/10.1016/j.amjmed.2008.06.030 PMID: 18954848

13. Siempos II, Maniatis NA, Kopterides P, Magkos C, Glycos C, Roussos C, et al. Pretreatment with atorvastatin attenuates lung injury caused by high-stretch mechanical ventilation in an isolated rabbit lung model. Critical care medicine. 2010; 38(5):1321–8. https://doi.org/10.1099/CCM.0b013e3181d9dad6 PMID: 20308883

14. Muller HC, Hellwig K, Rosseau S, Tschernig T, Schmiedl A, Gutbier B, et al. Simvastatin attenuates ventilator-induced lung injury in mice. Critical care. 2010; 14(4):R143. https://doi.org/10.1186/cc9209 PMID: 20673352

15. Bruyere R, Vigreron C, Prin S, Pechinot A, Quenot JP, Aho S, et al. Impact of prior statin therapy on the outcome of patients with suspected ventilator-associated pneumonia: an observational study. Critical care. 2014; 18(2):R83. https://doi.org/10.1186/cc13845 PMID: 24774941

16. McCauley D, Charles PE, Papazian L. Statins in patients with sepsis and ARDS: is it over? We are not sure. Intensive Care Med. 2016.

17. Barbar SD, Pauchard LA, Bruyere R, Bruillard C, Hayez D, Croisier D, et al. Mechanical Ventilation Alters the Development of Staphylococcus aureus Pneumonia in Rabbit. PLoS One. 2016; 11(7): e0158799. https://doi.org/10.1371/journal.pone.0158799 PMID: 27391952

18. Diep BA, Afasizheva A, Le HN, Kajikawa O, Matute-Bello G, Tkaczyk C, et al. Effects of Linezolid on Suppressing In Vivo Production of Staphylococcal Toxins and Improving Survival Outcomes in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Necrotizing Pneumonia. Journal of Infectious Diseases. 2013; 208(1):75–82. https://doi.org/10.1093/infdis/jit129 PMID: 23532096

19. Broccard A, Shapiro RS, Schmitz LL, Adams AB, Nahum A, Marini JJ. Prone positioning attenuates and redistributes ventilator-induced lung injury in dogs. Crit Care Med. 2008; 28(2):295–303. PMID: 17448939

20. Kajikawa O, Frevert CW, Lin SM, Goodman RB, Mongovin SM, Wong V, et al. Gene expression of Toll-like receptor-2, Toll-like receptor-4, and MD2 is differentially regulated in rabbits with Escherichia coli pneumonia. Gene. 2005; 344:193–202. https://doi.org/10.1016/j.gene.2004.09.032 PMID: 15656985

21. Slutsky AS, Ranieri VM. Ventilator-induced lung injury. N Engl J Med. 2013; 369(22):2126–36. https://doi.org/10.1056/NEJMr1208707 PMID: 24283226

22. Ladoire S, Pauchard LA, Barbar SD, Tissieres P, Croisier-Berton D, Charles PE. Impact of the prone position in an animal model of unilateral bacterial pneumonia undergoing mechanical ventilation. Anesthesiology. 2013; 118(5):1150–9. https://doi.org/10.1097/ALN.0b013e31828a7016 PMID: 23416383

23. Charles PE, Etienne M, Croisier D, Piroth L, Lequeu C, Pugin J, et al. The impact of mechanical ventilation on the moxifloxacin treatment of experimental pneumonia caused by Streplococcus pneumoniae. Critical care medicine. 2005; 33(5):1029–35. PMID: 15891332

24. Jacqueline C, Broquet A, Roquilly A, Davieau M, Caillon J, Altare F, et al. Linezolid dampens neutrophil-mediated inflammation in methicillin-resistant Staphylococcus aureus-induced pneumonia and protects the lung of associated damages. J Infect Dis. 2014; 210(5):814–23. https://doi.org/10.1093/infdis/jiu145 PMID: 24620024
25. Niessner A, Steiner S, Speidl WS, Pleiner J, Seidinger D, Maurer G, et al. Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis. 2006; 189(2):408–13. https://doi.org/10.1016/j.atherosclerosis.2005.12.022 PMID: 16443229

26. Shyamsundar M, McKeown ST, O’Kane CM, Craig TR, Brown V, Thickett DR, et al. Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. American journal of respiratory and critical care medicine. 2009; 179(12):1107–14. https://doi.org/10.1164/rccm.200810-1584OC PMID: 19324974

27. Chow OA, von Kockritz-Blickwedel M, Bright AT, Hensler ME, Zinkernagel AS, Cogen AL, et al. Statins enhance formation of phagocyte extracellular traps. Cell Host Microbe. 2010; 8(5):445–54. https://doi.org/10.1016/j.chom.2010.10.005 PMID: 21075355

28. Calisto KL, Carvalho Bde M, Ropelle ER, Mittesteller FC, Camacho AC, Guadagnini D, et al. Atorvastatin improves survival in septic rats: effect on tissue inflammatory pathway and on insulin signaling. PLoS One. 2010; 5(12):e14232. https://doi.org/10.1371/journal.pone.0014232 PMID: 21270944

29. Yoshizawa S, Tateda K, Saga T, Ishii Y, Yamanuchi K. Virulence-suppressing effects of linezolid on methicillin-resistant Staphylococcus aureus: possible contribution to early defervescence. Antimicrob Agents Chemother. 2012; 56(4):1744–8. https://doi.org/10.1128/AAC.05430-11 PMID: 22290944

30. Wang Y, Zhang MX, Meng X, Liu FQ, Yu GS, Zhang C, et al. Atorvastatin suppresses LPS-induced rapid upregulation of Toll-like receptor 4 and its signaling pathway in endothelial cells. Am J Physiol Heart Circ Physiol. 2011; 300(5):H1743–52. https://doi.org/10.1152/ajpheart.01335.2008 PMID: 21317307

31. Vaneker M, Joosten LA, Heunks LM, Snijdelaar DG, Halbertsma FJ, van Egmond J, et al. Low-tidal-volume mechanical ventilation induces a toll-like receptor 4-dependent inflammatory response in healthy mice. Anesthesiology. 2008; 109(3):465–72. https://doi.org/10.1097/ALN.0b013e3181822574 PMID: 18719444

32. Papazian L, Roch A, Charles PE, Penot-Ragon C, Perrin G, Roulier P, et al. Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial. Journal of Clinical Investigation. 2013; 130(16):1692–700. https://doi.org/10.1172/JCI1328030 PMID: 24108510

33. Makris D, Manoulakas E, Komnos A, Papakrivou E, Tzovaras N, Hovas A, et al. Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: open-label, randomized study. Critical care medicine. 2011; 39(11):2446–50. https://doi.org/10.1097/CCM.0b013e318225742c PMID: 21725239

34. Kruger P, Bailey M, Bellomo R, Cooper DJ, Harward M, Higgins A, et al. A Multicenter Randomized Trial of Atorvastatin Therapy in Intensive Care Patients with Severe Sepsis. American journal of respiratory and critical care medicine. 2013; 187(7):743–50. https://doi.org/10.1164/rccm.201209-1718OC PMID: 23348980

35. Christaki E, Giamarellos-Bourboulis EJ. The complex pathogenesis of bacteremia: from antimicrobial clearance mechanisms to the genetic background of the host. Virulence. 2014; 5(1):57–65. https://doi.org/10.4161/viru.26514 PMID: 24067507

36. Terragni PP, Rosboch G, Tealdi A, Corso E, Menaldo E, Davini O, et al. Tidal hyperinflation during low tidal volume ventilation in acute respiratory distress syndrome. American journal of respiratory and critical care medicine. 2007; 175(2):160–6. https://doi.org/10.1164/rccm.200607-915OC PMID: 17038660

37. Taubert M, Zoller M, Maier B, Frechen S, Scharf C, Holdt LM, et al. Predictors of inadequate linezolid concentrations after standard dosing in critically ill patients. Antimicrob Agents Chemother. 2016.